Neutrophil-to-Lymphocyte Ratio (NLR) Predicts PD-1 Inhibitor Survival in Patients with Metastatic Gastric Cancer
Background and Aims. Biomarkers for systemic inflammation have been introduced into clinical practice for risk-rating in cancer patients’ treatment. This study is aimed at confirming the prognostic role of the neutrophil-to-lymphocyte ratio (NLR) as an effective biomarker for patients with metastati...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2021/2549295 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850221024998588416 |
|---|---|
| author | Miaomiao Gou Tongtong Qu Zhikuan Wang Huan Yan Yanhai Si Yong Zhang Guanghai Dai |
| author_facet | Miaomiao Gou Tongtong Qu Zhikuan Wang Huan Yan Yanhai Si Yong Zhang Guanghai Dai |
| author_sort | Miaomiao Gou |
| collection | DOAJ |
| description | Background and Aims. Biomarkers for systemic inflammation have been introduced into clinical practice for risk-rating in cancer patients’ treatment. This study is aimed at confirming the prognostic role of the neutrophil-to-lymphocyte ratio (NLR) as an effective biomarker for patients with metastatic gastric cancer (MGC) receiving anti-PD-1 agents. Method. Patients with MGC who received anti-PD-1 treatment at the Chinese PLA General Hospital between January 2016 and November 2020 were reviewed. The study analyzed the association of NLR and overall survival (OS) or progression-free survival (PFS) and antitumor response rate with PD-1 inhibitors. Results. 137 patients were included in the final analysis. The area under the curve value of NLR for 6-month OS was 0.71. The best cut-off value for NLR was 3.23. NLR<3.23 was associated with longer OS (HR=0.38, 95% CI, 0.26-0.57, p<0.001) and PFS (HR=0.42, 95% CI, 0.29-0.62, p<0.001) in patients with MGC. No significant difference was observed in the objective response rate (ORR) (35.8% vs. 28.6%, p=0.377) and disease control rate (DCR) (86.4% vs. 78.6%, p=0.229) in the NLR<3.23 group and in the NLR≥3.23 group, respectively. Univariate analysis and multivariate analysis found that NLR was an independent prognosis biomarker for PFS and OS. Conclusions. Pretreatment elevated NLR was significantly associated with inferior PFS and OS in patients with MGC who received anti-PD-1 inhibitors. Clinicians need to consider patients with elevated NLR for decisions on immunotherapy strategy. |
| format | Article |
| id | doaj-art-74ad2af764af49bea3cf993a1aa1ce3a |
| institution | OA Journals |
| issn | 2314-7156 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-74ad2af764af49bea3cf993a1aa1ce3a2025-08-20T02:06:50ZengWileyJournal of Immunology Research2314-71562021-01-01202110.1155/2021/2549295Neutrophil-to-Lymphocyte Ratio (NLR) Predicts PD-1 Inhibitor Survival in Patients with Metastatic Gastric CancerMiaomiao Gou0Tongtong Qu1Zhikuan Wang2Huan Yan3Yanhai Si4Yong Zhang5Guanghai Dai6Medical Oncology DepartmentMedical Oncology DepartmentMedical Oncology DepartmentMedical Oncology DepartmentMedical Oncology DepartmentMedical Oncology DepartmentMedical Oncology DepartmentBackground and Aims. Biomarkers for systemic inflammation have been introduced into clinical practice for risk-rating in cancer patients’ treatment. This study is aimed at confirming the prognostic role of the neutrophil-to-lymphocyte ratio (NLR) as an effective biomarker for patients with metastatic gastric cancer (MGC) receiving anti-PD-1 agents. Method. Patients with MGC who received anti-PD-1 treatment at the Chinese PLA General Hospital between January 2016 and November 2020 were reviewed. The study analyzed the association of NLR and overall survival (OS) or progression-free survival (PFS) and antitumor response rate with PD-1 inhibitors. Results. 137 patients were included in the final analysis. The area under the curve value of NLR for 6-month OS was 0.71. The best cut-off value for NLR was 3.23. NLR<3.23 was associated with longer OS (HR=0.38, 95% CI, 0.26-0.57, p<0.001) and PFS (HR=0.42, 95% CI, 0.29-0.62, p<0.001) in patients with MGC. No significant difference was observed in the objective response rate (ORR) (35.8% vs. 28.6%, p=0.377) and disease control rate (DCR) (86.4% vs. 78.6%, p=0.229) in the NLR<3.23 group and in the NLR≥3.23 group, respectively. Univariate analysis and multivariate analysis found that NLR was an independent prognosis biomarker for PFS and OS. Conclusions. Pretreatment elevated NLR was significantly associated with inferior PFS and OS in patients with MGC who received anti-PD-1 inhibitors. Clinicians need to consider patients with elevated NLR for decisions on immunotherapy strategy.http://dx.doi.org/10.1155/2021/2549295 |
| spellingShingle | Miaomiao Gou Tongtong Qu Zhikuan Wang Huan Yan Yanhai Si Yong Zhang Guanghai Dai Neutrophil-to-Lymphocyte Ratio (NLR) Predicts PD-1 Inhibitor Survival in Patients with Metastatic Gastric Cancer Journal of Immunology Research |
| title | Neutrophil-to-Lymphocyte Ratio (NLR) Predicts PD-1 Inhibitor Survival in Patients with Metastatic Gastric Cancer |
| title_full | Neutrophil-to-Lymphocyte Ratio (NLR) Predicts PD-1 Inhibitor Survival in Patients with Metastatic Gastric Cancer |
| title_fullStr | Neutrophil-to-Lymphocyte Ratio (NLR) Predicts PD-1 Inhibitor Survival in Patients with Metastatic Gastric Cancer |
| title_full_unstemmed | Neutrophil-to-Lymphocyte Ratio (NLR) Predicts PD-1 Inhibitor Survival in Patients with Metastatic Gastric Cancer |
| title_short | Neutrophil-to-Lymphocyte Ratio (NLR) Predicts PD-1 Inhibitor Survival in Patients with Metastatic Gastric Cancer |
| title_sort | neutrophil to lymphocyte ratio nlr predicts pd 1 inhibitor survival in patients with metastatic gastric cancer |
| url | http://dx.doi.org/10.1155/2021/2549295 |
| work_keys_str_mv | AT miaomiaogou neutrophiltolymphocyterationlrpredictspd1inhibitorsurvivalinpatientswithmetastaticgastriccancer AT tongtongqu neutrophiltolymphocyterationlrpredictspd1inhibitorsurvivalinpatientswithmetastaticgastriccancer AT zhikuanwang neutrophiltolymphocyterationlrpredictspd1inhibitorsurvivalinpatientswithmetastaticgastriccancer AT huanyan neutrophiltolymphocyterationlrpredictspd1inhibitorsurvivalinpatientswithmetastaticgastriccancer AT yanhaisi neutrophiltolymphocyterationlrpredictspd1inhibitorsurvivalinpatientswithmetastaticgastriccancer AT yongzhang neutrophiltolymphocyterationlrpredictspd1inhibitorsurvivalinpatientswithmetastaticgastriccancer AT guanghaidai neutrophiltolymphocyterationlrpredictspd1inhibitorsurvivalinpatientswithmetastaticgastriccancer |